Korro Bio (KRRO) announced the appointment of Loic Vincent, Ph.D., as the Company’s Chief Scientific Officer. Prior to joining Korro, Dr.

Korro Bio's OPERA platform offers precise RNA editing for genetic diseases like Alpha-1 antitrypsin deficiency. Learn more on ...

Strengthens leadership team with additional key appointment of GaoZhong Zhu, Ph.D. as Senior Vice President of Chemistry, Manufacturing and Controls (CMC) & Technical Operations and promotion of ...

The Series B funds will support the launch of a Phase I/II clinical trial for AIR-001 to advance its RNA editing pipeline.

Shares of Korro Bio, Inc. (NASDAQ:KRRO – Get Free Report) have been assigned a consensus rating of “Buy” from the seven ...

In a report released today, Yasmeen Rahimi from Piper Sandler maintained a Buy rating on Korro Bio (KRRO – Research Report), with a price ...

Korro Bio, Inc. (NASDAQ:KRRO), a biotechnology company specializing in RNA editing therapies, has been making significant strides in the development of treatments for rare genetic disorders ...

Read Our Latest Stock Report on KRRO Korro Bio Trading Up 1.1 % KRRO stock opened at $24.03 on Monday. The firm has a 50-day moving average of $29.60 and a two-hundred day moving average of $41.23 ...

Korro Bio, Inc. (NASDAQ:KRRO), a biotechnology company specializing in RNA editing therapies, has been making significant strides in the development of treatments for rare genetic disorders, ...

So, the natural question for Korro Bio (NASDAQ:KRRO) shareholders is whether they should be concerned by its rate of cash burn. In this article, we define cash burn as its annual (negative) free cash ...